X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor, which is being evaluated for the treatment of hereditary angioedema attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. It is being evaluated in phase 2/3 trials for the prophylactic treatment of HAE Attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
PHVS416 (deucrictibant) is a bradykinin B2 receptor inhibitor small molecule drug candidate in oral soft gel capsule form for prophylaxis against hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
PHVS416 (deucrictibant) is an investigational softgel immediate-release capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, which is investigated for HAE attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Pharvaris will use the net proceeds to fund research and development of its drug candidates including, PHVS416 (deucrictibant), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, being developed for hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: General Atlantic
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 20, 2023
Details:
The proceeds from the Series C financing will fund the clinical advancement of Pharvaris’ pipeline of novel oral bradykinin-B2-receptor antagonists for the treatment of HAE, including both on-demand treatment and prophylactic prevention.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
